Related Experiment Video
Updated: Feb 21, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer
Steven P Williams1, Andrew S Barthorpe1, Howard Lightfoot1
1Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Abstract:
Metastatic colorectal cancer is a leading cause of cancer death. However, current therapy options are limited to chemotherapy, with the addition of anti-EGFR antibodies for patients with RAS wild-type tumours. Novel drug targets, or drug combinations that induce a synergistic response, would be of great benefit to patients. The identification of genes that are essential for cell survival can be undertaken using functional genomics screens. Furthermore, performing such screens in the presence of a targeted agent would allow the identification of combinations that result in a synthetic lethal interaction. Here, we present a dataset containing the results of a large scale RNAi screen (815 genes) to detect essential genes as well as synergistic combinations with targeted therapeutic agents using a panel of 27 colorectal cancer cell lines. These data identify genes that are essential for colorectal cancer cell survival as well as synthetic lethal treatment combinations using novel computational approaches. Moreover, this dataset could be utilised in combination with genomic profiling to identify predictive biomarkers of response.
Insights
Researchers identified essential genes and synergistic drug combinations for treating metastatic colorectal cancer. This study utilized functional genomics screens to find novel therapeutic strategies beyond current chemotherapy options.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Metastatic colorectal cancer (mCRC) is a significant cause of cancer mortality.
- Current mCRC treatments are limited, primarily to chemotherapy, with anti-EGFR antibodies for RAS wild-type tumors.
- There is a critical need for novel therapeutic targets and synergistic drug combinations to improve patient outcomes.
Purpose of the Study:
- To identify genes essential for colorectal cancer cell survival.
- To discover synergistic drug combinations for mCRC treatment using functional genomics screens.
- To generate a dataset for identifying novel therapeutic strategies and predictive biomarkers.
Main Methods:
- Conducted a large-scale RNA interference (RNAi) screen targeting 815 genes.
- Utilized a panel of 27 colorectal cancer cell lines.
- Employed computational approaches to analyze screening data and identify synthetic lethal interactions.
Main Results:
- Identified a set of genes crucial for colorectal cancer cell survival.
- Discovered several synthetic lethal treatment combinations with targeted therapeutic agents.
- Generated a comprehensive dataset from the RNAi screen.
Conclusions:
- The study provides valuable insights into essential genes and synergistic drug combinations for mCRC.
- The dataset can accelerate the discovery of novel therapeutic strategies for colorectal cancer.
- Future research can integrate this dataset with genomic profiling to identify biomarkers predicting treatment response.
